Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Mortality results from a randomized prostate-cancer screening trial.
- G. Andriole, E. Crawford, +21 authors C. Berg
- Medicine
- The New England journal of medicine
- 16 December 2009
BACKGROUND
The effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the… Expand
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
- J. Mcconnell, C. Roehrborn, +23 authors J. Smith
- Medicine
- The New England journal of medicine
- 18 December 2003
BACKGROUND
Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or… Expand
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
- W. Catalona, Deborah S. Smith, +5 authors G. Andriole
- Medicine
- The New England journal of medicine
- 25 April 1991
BACKGROUND
Prostate-specific antigen (PSA) is secreted exclusively by prostatic epithelial cells, and its serum concentration is increased in men with prostatic disease, including cancer. We… Expand
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
Recently, common variants on human chromosome 8q24 were found to be associated with prostate cancer risk. While conducting a genome-wide association study in the Cancer Genetic Markers of… Expand
Effect of dutasteride on the risk of prostate cancer.
- G. Andriole, D. Bostwick, +11 authors R. Rittmaster
- Medicine
- The New England journal of medicine
- 8 April 2010
BACKGROUND
We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease.
METHODS
In… Expand
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
- P. Prorok, G. Andriole, +19 authors J. Gohagan
- Medicine
- Controlled clinical trials
- 1 December 2000
The objectives of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial are to determine in screenees ages 55-74 at entry whether screening with flexible sigmoidoscopy (60-cm… Expand
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
- G. Andriole, E. Crawford, +21 authors P. Prorok
- Medicine
- Journal of the National Cancer Institute
- 18 January 2012
BACKGROUND
The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was undertaken to determine whether there is a reduction in prostate cancer mortality… Expand
Multiple loci identified in a genome-wide association study of prostate cancer
- G. Thomas, K. Jacobs, +36 authors S. Chanock
- Biology, Medicine
- Nature Genetics
- 1 March 2008
We followed our initial genome-wide association study (GWAS) of 527,869 SNPs on 1,172 individuals with prostate cancer and 1,157 controls of European origin—nested in the Prostate, Lung, Colorectal,… Expand
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
- S. Buys, E. Partridge, +28 authors C. Berg
- Medicine
- JAMA
- 8 June 2011
CONTEXT
Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality.
OBJECTIVE
To evaluate the effect of screening for ovarian… Expand
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
- C. Roehrborn, P. Boyle, J. Nickel, K. Hoefner, G. Andriole
- Medicine
- Urology
- 1 September 2002
OBJECTIVES
To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II.
METHODS
A total of 4325 men (2951 completed) with clinical benign… Expand
...
1
2
3
4
5
...